PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company’s stockholders.
For a free consultation, please visit https://julieholleman.com/iovance-biotherapeutics-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].
According to a complaint recently filed in federal court, Iovance and its executives misled investors by exaggerating the company’s financial prospects and downplaying risk factors affecting the company’s growth potential. Among other things, the complaint alleges that the company concealed that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating legal claims against Iovance, its executives, and potentially also the company’s board of directors.
FIRM INFORMATION
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm’s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/iovance-shareholders-should-contact-shareholder-rights-firm-regarding-potential-legal-claims-302458275.html
SOURCE Julie & Holleman LLP
